Personalized cell therapy involves isolation of a person's own cells and modification of those cells to treat diseases. It is an evolving modality for treating various diseases such as cancer and autoimmune disorders. In personalized cell therapy, cells are extracted from the patient and modified outside the body to develop targeted cell-based therapies. For instance, in CAR T-cell therapy for cancer, T cells are extracted from the patient's blood and genetically modified to create chimeric antigen receptor (CAR) T cells that are infused back into the patient to target specific cancer cells. The global personalized cell therapy market is estimated to be valued at US$ 6.41 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growing prevalence of cancer diseases is expected to flourish the personalized cell therapy market during the forecast period. According to the American Cancer Society, approximately 1.9 million new cancer cases will be diagnosed in the United States in 2022. Furthermore, cancer is one of the leading causes of death worldwide. Personalized cell therapies have demonstrated promising results in the treatment of various cancer types due to their targeted approach. For instance, CAR T-cell therapies have shown durable responses in leukemia and lymphoma treatment. The growing cancer burden and limitations of conventional cancer therapies are creating demand for advanced targeted cell therapies, thereby driving the market growth.
The expanding application of personalized cell therapies in various disease indications beyond cancer, such as neurological diseases and rare genetic disorders, is also fueling the market growth. Ongoing research and development activities for developing newer forms of cell therapies using stem cells, T cells, and NK cells for treating hard-to-cure diseases will further present lucrative opportunities in the personalized cell therapy market during the forecast period.
Segment Analysis
The personalized cell therapy market can be segmented based on therapy type, therapeutic area, end-user and region. Based on therapy type, the market is segmented into autologous cell therapy and allogenic cell therapy. The autologous cell therapy segment currently dominates the market due to reduced risk of rejection and higher potency of autologous cells compared to allogenic cells.
PEST Analysis
Political: Government regulations around personalized cell therapies are still evolving. Strict approval protocols need to be followed for clinical trials and marketing.
Economic: The rising incidence of chronic diseases and increasing healthcare budgets are driving growth in the personalized cell therapy market. However, high costs of R&D and therapies pose challenges.
Social: Growing awareness among people about personalized medicine and its benefits is positively impacting the market. However, social and ethical concerns around stem cell research act as a restraint.
Technological: Advancements in stem cell biology, gene therapy and bioprocessing techniques are expanding the applications of personalized cell therapies. Developments in induced pluripotent stem cell technology are also fueling market opportunities.
Key Takeaways
The global Personalized Cell Therapy Market Growth is expected to witness high growth over the forecast period of 2024 to 2031. Autologous cell therapy is anticipated to remain the largest segment during this period due to its advantages over allogeneic therapy.
From a regional perspective, North America is likely to dominate the global market through 2031 on account of established healthcare infrastructure, high adoption of advanced therapies and strong presence of key players such as Continental AG, Valeo, Robert Bosch, Denso Corporation.
Key players operating in the personalized cell therapy market are Continental AG, Valeo, Robert Bosch, Denso Corporation. Continental AG is a leading player focused on investing in stem cell research. Robert Bosch and Denso Corporation are also innovating in gene therapy technologies to expand their cell therapy product portfolios.
For more insights, read- https://www.insightprobing.com/personalized-cell-therapy-market-trends-size-and-share-analysis/
For more details on the report, Read- https://masstamilan.tv/parp-inhibitors-a-promising-class-of-drugs-in-cancer-treatment/
